Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies

• Published in: Journal of clinical psychopharmacology Vol. 32; no. 3; p. 408
• Main Authors: Ayan-Oshodi, Mosun, Wondmagegnehu, Eshetu T, Lowe, Stephen L, Kryzhanovskaya, Ludmila, Walker, Daniel J, Kinon, Bruce J
• Format: Journal Article
• Language: English
• Published: United States 01.06.2012
• Subjects: Adult; Aged; Amino Acids - administration & dosage; Amino Acids - adverse effects; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Prodrugs - administration & dosage; Prodrugs - adverse effects; Receptors, Metabotropic Glutamate - agonists; Young Adult

Ten phase 1 studies of LY2140023 monohydrate (LY2140023), an mGlu2/3 receptor agonist, in healthy male and female subjects were pooled to evaluate the adverse event profile. These studies included both single-dose (5-200 mg) and multiple-dose (20-160 mg 2 times a day) treatment groups. The percentag...